2,6-Difluorobenzonitrile | CAS:1897-52-5

We serve 2,6-Difluorobenzonitrile CAS:1897-52-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,6-Difluorobenzonitrile

Chemical Name:2,6-Difluorobenzonitrile
CAS.NO:1897-52-5
Synonyms:2,6-Difluorobenzonitrile
2,6-difluoro-benzonitrile
Molecular Formula:C7H3F2N
Molecular Weight:139.10200
 
Physical and Chemical Properties:
Density:1.246
Melting point:25-28ºC
Boiling point:197-198ºC
Flash point:176°F
Index of Refraction:1.4875
 
Specification:
Appearance:Light yellow liquid
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Pesticide intermediates



Contact us for information like 2,6-Difluorobenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-difluoro-benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,6-Difluorobenzonitrile Use and application,2,6-difluoro-benzonitrile technical grade,usp/ep/jp grade.


Related News: Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.2-[4-[bis(2-hydroxyethyl)amino]-2-nitroanilino]ethanol manufacturer The recent promotion of TCM in China is also in line with Xi’s push to revive traditional Chinese culture, breaking away from the ruling Communist Party’s earlier path under late Chairman Mao Zedong, during which time elements of traditional culture were often attacked, especially during the Cultural Revolution.2-Cyano-3-fluoropyridine supplier APIs are generally manufactured through a variety of processes that include.L-CYSTEINE HCL H2O vendor With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.